Abstract
Glaucoma is the second leading cause for blindness worldwide. It is mainly caused by glaucomatous optic neuropathy (GON) characterized by retinal ganglion cell loss, which leads to visual field defect and blindness. Up to now, the main purpose of antiglaucomatous therapies has been to lower intraocular pressure (IOP) through surgeries and medications. However, it has been found that progressive GON is still present in some patients with effective IOP decrease. Therefore, risk factors other than IOP elevation, like neurotrophin deprivation and excitotoxicity, contribute to progressive GON. Novel approaches of neuroprotection may be more effective for preserving the function of the optic nerve.
Citations
Apr 20, 2016·Frontiers in Aging Neuroscience·Pawel GriebRobert Rejdak
Mar 13, 2017·Parkinsonism & Related Disorders·Merel S EkkerBastiaan R Bloem
Jan 2, 2018·BioResearch Open Access·Walter H MoosKrishna Kodukula
Feb 17, 2018·Chinese Medical Journal·Ya-Long DangUNKNOWN China Trabectome Study Group
Jun 2, 2018·Chinese Medical Journal·Xiao WangChun Zhang
Sep 24, 2019·Frontiers in Neuroscience·Teresa TsaiStephanie C Joachim
Jan 14, 2016·Military Medical Research·Eric L SingmanTimothy McCulley
Dec 13, 2018·Neural Regeneration Research·Annagrazia AdornettoVincenzo Parisi
Feb 9, 2018·Frontiers in Pharmacology·Ana C Rodrigues-NevesAna R Santiago
Dec 14, 2018·Frontiers in Neuroscience·Marita Pietrucha-DutczakAdrian Smedowski
Oct 16, 2020·Vestnik oftalmologii·V V StrakhovD A Dorofeev
Feb 15, 2021·Survey of Ophthalmology·Luciano QuarantaIvano Riva
Dec 31, 2020·Pharmaceutics·Ognjenka RahićEdina Vranić
Apr 6, 2021·Neural Regeneration Research·Lidawani LambukNafeeza Mohd Ismail
Aug 28, 2021·Foods·Claudio MolinariFrancesca Uberti
Mar 21, 2019·Neuro-degenerative Diseases·Makayla McCoskeyJoan M O Apos Brien